{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:44:54Z","timestamp":1793781894269,"version":"4.6.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T00:00:00Z","timestamp":1625702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["P30 DK120515"],"award-info":[{"award-number":["P30 DK120515"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.cgh.2021.02.043","type":"journal-article","created":{"date-parts":[[2021,3,7]],"date-time":"2021-03-07T09:16:09Z","timestamp":1615108569000},"page":"591-601.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"title":["Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status"],"prefix":"10.1016","volume":"20","author":[{"given":"William J.","family":"Sandborn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ala I.","family":"Sharara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinyu","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Modesto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Mundayat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Mert","family":"Gunay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Salese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce E.","family":"Sands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2021.02.043_bib1","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2021.02.043_bib2","doi-asserted-by":"crossref","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG clinical guideline: ulcerative colitis in adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2021.02.043_bib3","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1097\/MEG.0000000000000378","article-title":"Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn's disease: a systematic review and clinician surveys","volume":"27","author":"Gordon","year":"2015","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.02.043_bib4","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/ibd\/izy327","article-title":"A\u00a0state-of-the-art review of new and emerging therapies for the treatment of IBD","volume":"25","author":"Chudy-Onwugaje","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2021.02.043_bib5","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/imj.12397","article-title":"Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy","volume":"44","author":"Subramaniam","year":"2014","journal-title":"Intern Med J"},{"key":"10.1016\/j.cgh.2021.02.043_bib6","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.crohns.2012.10.004","article-title":"Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome","volume":"7","author":"Garc\u00eda-Bosch","year":"2013","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2021.02.043_bib7","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.cgh.2016.08.044","article-title":"Efficacy of vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists","volume":"15","author":"Feagan","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2021.02.043_bib8","first-page":"S181","article-title":"Efficacy in biologic-failure and nonbiologic-failure populations in a phase 3 study of ustekinumab in moderate-severe ulcerative colitis: UNIFI [abstract 833a]","volume":"156","author":"Sands","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2021.02.043_bib9","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1112168","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis","volume":"367","author":"Sandborn","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2021.02.043_bib10","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2021.02.043_bib11","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.1093\/ecco-jcc\/jjz203.100","article-title":"Tofacitinib, an oral, small-molecule Janus kinase inhibitor, in the treatment of ulcerative colitis: analysis of an open-label, long-term extension study with up to 5.9 years of treatment [abstract DOP61]","volume":"14","author":"Lichtenstein","year":"2020","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2021.02.043_bib12","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1093\/ibd\/izy131","article-title":"Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib","volume":"24","author":"Winthrop","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2021.02.043_bib13","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1093\/ibd\/izy150","article-title":"Herpes zoster in patients receiving JAK inhibitors for ulcerative colitis: mechanism, epidemiology, management, and prevention","volume":"24","author":"Colombel","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2021.02.043_bib14","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1080\/03007995.2020.1716701","article-title":"Efficacy of ustekinumab vs. advanced therapies for the treatment of moderately to severely active ulcerative colitis: a systematic review and network meta-analysis","volume":"36","author":"Welty","year":"2020","journal-title":"Curr Med Res Opin"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2021.02.043_bib15","doi-asserted-by":"crossref","first-page":"S537","DOI":"10.1093\/ecco-jcc\/jjz203.781","article-title":"Efficacy and safety of an additional 8 weeks of tofacitinib induction therapy: updated results of the OCTAVE Open study for tofacitinib 8-week induction non-responders [abstract P653]","volume":"14","author":"Rubin","year":"2020","journal-title":"J\u00a0Crohns Colitis"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2021.02.043_bib17","doi-asserted-by":"crossref","first-page":"S425","DOI":"10.1093\/ecco-jcc\/jjy222.743","article-title":"Maintenance of efficacy following tofacitinib dose reduction in patients with ulcerative colitis in stable remission [abstract P619]","volume":"13","author":"Rubin","year":"2019","journal-title":"J\u00a0Crohns Colitis"},{"issue":"Suppl 10","key":"10.1016\/j.cgh.2021.02.043_bib19","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1002\/art.38745","article-title":"Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis","volume":"66","author":"Winthrop","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.cgh.2021.02.043_bib20","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jaad.2017.03.023","article-title":"Herpes zoster in psoriasis patients treated with tofacitinib","volume":"77","author":"Winthrop","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.cgh.2021.02.043_bib21","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1053\/j.gastro.2012.05.004","article-title":"Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease","volume":"143","author":"Long","year":"2012","journal-title":"Gastroenterology"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356521002226?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356521002226?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:38:18Z","timestamp":1761543498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356521002226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S1542356521002226"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2021.02.043","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2021.02.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc. on behalf of the AGA Institute","name":"copyright","label":"Copyright"}]}}